Active — Not RecruitingNot Applicable

Whole-Body Vibration in Parkinson Disease

Turkey (Türkiye)66 participantsStarted 2026-01-20

Plain-language summary

The aim of this study is to evaluate the effects of different frequencies of Whole Body Vibration (WBV) application on balance, gait, cognitive functions, and dual-task performance in patients with Parkinson's disease. Study Hypotheses: H0.1 - There is no effect of different frequencies of WBV application on balance performance in patients with Parkinson's disease. H1.1 - There is an effect of different frequencies of WBV application on balance performance in patients with Parkinson's disease. H0.2 - There is no effect of different frequencies of WBV application on gait performance in patients with Parkinson's disease. H1.2 - There is an effect of different frequencies of WBV application on gait performance in patients with Parkinson's disease. H0.3 - There is no effect of different frequencies of WBV application on cognitive functions in patients with Parkinson's disease. H1.3 - There is an effect of different frequencies of WBV application on cognitive functions in patients with Parkinson's disease. H0.4 - There is no effect of different frequencies of WBV application on dual-task performance in patients with Parkinson's disease. H1.4 - There is an effect of different frequencies of WBV application on dual-task performance in patients with Parkinson's disease. H0.5 - There is no effect of different frequencies of WBV application on reaction time in patients with Parkinson's disease. H1.5 - There is an effect of different frequencies of WBV application on reaction time in patients with Parkinson's disease. H0.6 - There is no significant difference between medium-frequency and low-frequency WBV in terms of balance performance in patients with Parkinson's disease. H1.6 - There is a significant difference between medium-frequency and low-frequency WBV in terms of balance performance in patients with Parkinson's disease. H0.7 - There is no significant difference between medium-frequency and low-frequency WBV in terms of gait performance in patients with Parkinson's disease. H1.7 - There is a significant difference between medium-frequency and low-frequency WBV in terms of gait performance in patients with Parkinson's disease. H0.8 - There is no significant difference between medium-frequency and low-frequency WBV in terms of cognitive functions in patients with Parkinson's disease. H1.8 - There is a significant difference between medium-frequency and low-frequency WBV in terms of cognitive functions in patients with Parkinson's disease. H0.9 - There is no significant difference between medium-frequency and low-frequency WBV in terms of dual-task performance in patients with Parkinson's disease. H1.9 - There is a significant difference between medium-frequency and low-frequency WBV in terms of dual-task performance in patients with Parkinson's disease. H0.10 - There is no significant difference between medium-frequency and low-frequency WBV in terms of reaction time in patients with Parkinson's disease. H1.10 - There is a significant difference between medium-frequency and low-frequency WBV in terms of reaction time in patients with Parkinson's disease.

Who can participate

Age range

30 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * Individuals aged 30-80 years with a clinical diagnosis of Parkinson's disease. Hoehn and Yahr stages 1-3. * Stable medical treatment (no changes in medication for the past 4 weeks). * Willingness to participate and provision of written informed consent. * Score of 24 or higher on the Standardized Mini Mental State Examination (SMMSE). Exclusion Criteria * Advanced stage Parkinson's disease (Hoehn and Yahr stage \>3) or presence of severe motor complications. * History of surgical interventions or other neurological/vestibular disorders that may affect balance and gait (E.G., stroke, epilepsy, peripheral neuropathy). * Presence of severe cardiovascular or respiratory conditions that may affect stability (E.G., heart failure, uncontrolled hypertension, advanced COPD). * Conditions contraindicating whole-body vibration (WBV) application (E.G., severe osteoporosis, active thrombosis). * Psychiatric disorders or major depression that may interfere with treatment participation. * Significant communication or language impairments affecting participation. Withdrawal Criteria * Voluntary withdrawal from the study. * Development of health problems during the intervention that prevent completion of the study (E.G., unexpected acute illness or temporary medical condition). * Changes in medication or medical status during the study that may affect participation or performance. * Non-adherence to the protocol (attendance rate below 80% of sessions).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Mini Balance Evaluation Systems Test (Mini-BESTest)

Timeframe: Baseline and 8 weeks

10 Meter Walk Test (10MWT)

Timeframe: Baseline and 8 weeks

Trial details

NCT IDNCT07678983

SponsorIzmir Bakircay University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Parkinson's Disease trials